ACADIA Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ACAD and other ETFs, options, and stocks.

About ACAD

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. 

CEO
Catherine Owen Adams
CEOCatherine Owen Adams
Employees
798
Employees798
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1993
Founded1993
Employees
798
Employees798

ACAD Key Statistics

Market cap
4.34B
Market cap4.34B
Price-Earnings ratio
10.80
Price-Earnings ratio10.80
Dividend yield
Dividend yield
Average volume
2.15M
Average volume2.15M
High today
$28.00
High today$28.00
Low today
$24.79
Low today$24.79
Open price
$26.38
Open price$26.38
Volume
7.37M
Volume7.37M
52 Week high
$28.35
52 Week high$28.35
52 Week low
$19.69
52 Week low$19.69

Stock Snapshot

ACADIA Pharmaceuticals(ACAD) stock is priced at $25.25, giving the company a market capitalization of 4.34B. It carries a P/E multiple of 10.80.

As of 2026-06-26, ACADIA Pharmaceuticals(ACAD) stock has fluctuated between $24.79 and $28.00. The current price stands at $25.25, placing the stock +1.9% above today's low and -9.8% off the high.

The ACADIA Pharmaceuticals(ACAD)'s current trading volume is 7.37M, compared to an average daily volume of 2.15M.

During the past year, ACADIA Pharmaceuticals(ACAD) stock moved between $19.69 at its lowest and $28.35 at its peak.

During the past year, ACADIA Pharmaceuticals(ACAD) stock moved between $19.69 at its lowest and $28.35 at its peak.

ACAD News

TipRanks 5h
Buy Rating Reiterated on ACADIA as EU Rett Prospects Strengthen; $37 Price Target Unchanged

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on ACADIA Pharmaceuticals, with a price target of $37.00. Unlock powerful investin...

Benzinga 9h
Acadia Pharma Stock Jumps After European Panel Reverses Course On Rett Syndrome Therapy - Benzinga

...

Acadia Pharma Stock Jumps After European Panel Reverses Course On Rett Syndrome Therapy - Benzinga
TipRanks 10h
Acadia Pharmaceuticals rises 13.4%

Acadia Pharmaceuticals (ACAD) is up 13.4%, or $3.17 to $26.89. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confiden...

Analyst ratings

76%

of 21 ratings
Buy
76.2%
Hold
19%
Sell
4.8%

More ACAD News

TipRanks 11h
Acadia Pharmaceuticals Stock Jumps on a Positive CHMP Review

Acadia Pharmaceuticals (ACAD) stock rallied on Friday alongside an update from the biopharmaceutical company. It said that the European Medicines Agency (EMA)’s...

Simply Wall St 4d
ACADIA Pharmaceuticals Stock Could Be 23.2% Undervalued After Guidance Reaffirmed

ACADIA Pharmaceuticals (ACAD) has drawn fresh attention after filing a shelf registration for up to 5,209,670 common shares, valued at about $113.8 million and...

ACADIA Pharmaceuticals Stock Could Be 23.2% Undervalued After Guidance Reaffirmed

People also own

Based on the portfolios of people who own ACAD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.